Cargando…

Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer

Background: Although combination immunotherapies incorporating local and systemic components have shown promising results in treating solid tumors, varied tumor microenvironments (TMEs) can impact immunotherapeutic efficacy. Method: We designed and evaluated treatment strategies for breast and pancr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, James, Fite, Brett Z., Kare, Aris J., Wu, Bo, Raie, Marina, Tumbale, Spencer K., Zhang, Nisi, Davis, Ryan R., Tepper, Clifford G., Aviran, Sharon, Newman, Aaron M., King, Daniel A., Ferrara, Katherine W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706583/
https://www.ncbi.nlm.nih.gov/pubmed/36451859
http://dx.doi.org/10.7150/thno.73218
_version_ 1784840535995842560
author Wang, James
Fite, Brett Z.
Kare, Aris J.
Wu, Bo
Raie, Marina
Tumbale, Spencer K.
Zhang, Nisi
Davis, Ryan R.
Tepper, Clifford G.
Aviran, Sharon
Newman, Aaron M.
King, Daniel A.
Ferrara, Katherine W.
author_facet Wang, James
Fite, Brett Z.
Kare, Aris J.
Wu, Bo
Raie, Marina
Tumbale, Spencer K.
Zhang, Nisi
Davis, Ryan R.
Tepper, Clifford G.
Aviran, Sharon
Newman, Aaron M.
King, Daniel A.
Ferrara, Katherine W.
author_sort Wang, James
collection PubMed
description Background: Although combination immunotherapies incorporating local and systemic components have shown promising results in treating solid tumors, varied tumor microenvironments (TMEs) can impact immunotherapeutic efficacy. Method: We designed and evaluated treatment strategies for breast and pancreatic cancer combining magnetic resonance-guided focused ultrasound (MRgFUS) ablation and antibody therapies. With a combination of single-cell sequencing, spectral flow cytometry, and histological analyses, we profiled an immune-suppressed KPC (Kras(+/LSL-G12D); Trp53(+/LSL-R172H); Pdx1-Cre) pancreatic adenocarcinoma (MT4) model and a dense epithelial neu deletion (NDL) HER2(+) mammary adenocarcinoma model with a greater fraction of lymphocytes, natural killer cells and activated dendritic cells. We then performed gene ontology analysis, spectral and digital cytometry to assess the immune response to combination immunotherapies and correlation with survival studies. Result: Based on gene ontology analysis, adding ablation to immunotherapy enriched immune cell migration pathways in the pancreatic cancer model and extensively enriched wound healing pathways in the breast cancer model. With CIBERSORTx digital cytometry, aCD40 + aPD-1 immunotherapy combinations enhanced dendritic cell activation in both models. In the MT4 TME, adding the combination of aCD40 antibody and checkpoint inhibitors (aPD-1 and aCTLA-4) with ablation was synergistic, increasing activated natural killer cells and T cells in distant tumors. Furthermore, ablation with immunotherapy upregulated critical Ly6c myeloid remodeling phenotypes that enhance T-cell effector function and increased granzyme and protease encoding genes by as much as 100-fold. Ablation combined with immunotherapy then extended survival in the MT4 model to a greater extent than immunotherapy alone. Conclusion: In summary, TME profiling informed a successful multicomponent treatment protocol incorporating ablation and facilitated differentiation of TMEs in which ablation is most effective.
format Online
Article
Text
id pubmed-9706583
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-97065832022-11-29 Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer Wang, James Fite, Brett Z. Kare, Aris J. Wu, Bo Raie, Marina Tumbale, Spencer K. Zhang, Nisi Davis, Ryan R. Tepper, Clifford G. Aviran, Sharon Newman, Aaron M. King, Daniel A. Ferrara, Katherine W. Theranostics Research Paper Background: Although combination immunotherapies incorporating local and systemic components have shown promising results in treating solid tumors, varied tumor microenvironments (TMEs) can impact immunotherapeutic efficacy. Method: We designed and evaluated treatment strategies for breast and pancreatic cancer combining magnetic resonance-guided focused ultrasound (MRgFUS) ablation and antibody therapies. With a combination of single-cell sequencing, spectral flow cytometry, and histological analyses, we profiled an immune-suppressed KPC (Kras(+/LSL-G12D); Trp53(+/LSL-R172H); Pdx1-Cre) pancreatic adenocarcinoma (MT4) model and a dense epithelial neu deletion (NDL) HER2(+) mammary adenocarcinoma model with a greater fraction of lymphocytes, natural killer cells and activated dendritic cells. We then performed gene ontology analysis, spectral and digital cytometry to assess the immune response to combination immunotherapies and correlation with survival studies. Result: Based on gene ontology analysis, adding ablation to immunotherapy enriched immune cell migration pathways in the pancreatic cancer model and extensively enriched wound healing pathways in the breast cancer model. With CIBERSORTx digital cytometry, aCD40 + aPD-1 immunotherapy combinations enhanced dendritic cell activation in both models. In the MT4 TME, adding the combination of aCD40 antibody and checkpoint inhibitors (aPD-1 and aCTLA-4) with ablation was synergistic, increasing activated natural killer cells and T cells in distant tumors. Furthermore, ablation with immunotherapy upregulated critical Ly6c myeloid remodeling phenotypes that enhance T-cell effector function and increased granzyme and protease encoding genes by as much as 100-fold. Ablation combined with immunotherapy then extended survival in the MT4 model to a greater extent than immunotherapy alone. Conclusion: In summary, TME profiling informed a successful multicomponent treatment protocol incorporating ablation and facilitated differentiation of TMEs in which ablation is most effective. Ivyspring International Publisher 2022-11-14 /pmc/articles/PMC9706583/ /pubmed/36451859 http://dx.doi.org/10.7150/thno.73218 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wang, James
Fite, Brett Z.
Kare, Aris J.
Wu, Bo
Raie, Marina
Tumbale, Spencer K.
Zhang, Nisi
Davis, Ryan R.
Tepper, Clifford G.
Aviran, Sharon
Newman, Aaron M.
King, Daniel A.
Ferrara, Katherine W.
Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
title Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
title_full Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
title_fullStr Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
title_full_unstemmed Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
title_short Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
title_sort multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706583/
https://www.ncbi.nlm.nih.gov/pubmed/36451859
http://dx.doi.org/10.7150/thno.73218
work_keys_str_mv AT wangjames multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT fitebrettz multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT karearisj multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT wubo multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT raiemarina multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT tumbalespencerk multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT zhangnisi multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT davisryanr multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT teppercliffordg multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT aviransharon multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT newmanaaronm multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT kingdaniela multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer
AT ferrarakatherinew multiomicanalysisforoptimizationofcombinedfocalandimmunotherapyprotocolsinmurinepancreaticcancer